Headlines about Celgene (NASDAQ:CELG) have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Celgene earned a news impact score of 0.06 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.1433954816441 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have impacted Accern’s rankings:
- David Rolfe Comments on Celgene (finance.yahoo.com)
- Top VC deals: Jaguar backs robo-taxis, Google buys Redux, Celgene buys new cancer drugs (cnbc.com)
- Celgene Co. (CELG) Given Consensus Recommendation of “Buy” by Analysts (americanbankingnews.com)
- Wait, It Costs How Much? Biotech Balances Optimism, Uncertainty For 2018 (finance.yahoo.com)
- Biopharma company Celgene is set to acquire Impact Biomedicines (healthcareglobal.com)
Shares of Celgene (NASDAQ CELG) opened at $106.00 on Friday. Celgene has a 12-month low of $94.55 and a 12-month high of $147.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. The firm has a market capitalization of $83,460.00, a P/E ratio of 25.00, a PEG ratio of 0.68 and a beta of 1.77.
Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. Celgene’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the prior year, the business earned $1.58 earnings per share. sell-side analysts anticipate that Celgene will post 6.69 EPS for the current fiscal year.
Several equities analysts have recently issued reports on CELG shares. Cantor Fitzgerald reissued a “buy” rating and set a $162.00 price target on shares of Celgene in a report on Tuesday, September 26th. Robert W. Baird reaffirmed a “buy” rating and issued a $162.00 price objective on shares of Celgene in a report on Thursday, September 21st. Vetr raised shares of Celgene from a “hold” rating to a “buy” rating and set a $146.58 price objective for the company in a report on Friday, October 6th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $173.00 price objective on shares of Celgene in a report on Thursday, October 5th. Finally, JPMorgan Chase & Co. reissued a “buy” rating on shares of Celgene in a report on Monday, October 16th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nineteen have issued a buy rating to the company’s stock. Celgene has an average rating of “Buy” and a consensus target price of $131.18.
WARNING: “Celgene (CELG) Receives Daily News Impact Score of 0.06” was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.thelincolnianonline.com/2018/01/14/celgene-celg-receives-news-sentiment-rating-of-0-06-updated-updated.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.